GenusGENSY 55 EBITDA Margin % is 20.83% as of Dec. 2025, which is 48% above its 10-year median of 14.11. GuruFocus rates GENSY with a GF Score™ of 55/100 and a GF Value™ of $29.86 (Fairly Valued). The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, Genus ranks better than 81.89% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Genus's EBITDA for the
six
months ended in Dec. 2025 was $93.6 Mil. Genus's Revenue for the
six
months ended in Dec. 2025 was $449.3 Mil. Therefore, Genus's EBITDA margin for the quarter that ended in Dec. 2025 was 20.83%.
Genus (OTCPK:GENSY) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Genus EBITDA Margin % Related Terms
Genus EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Genus's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
GENSY vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Genus's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genus EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genus's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Genus's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genus (GENSY) has a EBITDA Margin % of 20.83% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genus and its competitors. This is 48% above median its historical median of 14.11. Over the past decade, Genus' EBITDA Margin % has ranged from 7.74 to 20.60. According to the industry distribution chart, Genus ranks #171 out of 944 companies in the Biotechnology industry, placing it in the top 18.1%.
Is Genus' EBITDA Margin % too high?
Genus' current EBITDA Margin % of 20.83% is 48% above median its 10-year median of 14.11. Over the past 10 years, this metric has ranged from a low of 7.74 to a high of 20.60. Based on the distribution chart, Genus ranks #171 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Genus has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genus' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genus ranks #171 out of 944 companies for EBITDA Margin %. This places Genus in the top 18% of its industry — outperforming the majority of peers. Historically, Genus' own EBITDA Margin % has ranged from 7.74 to 20.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Genus and its competitors. Genus's current EBITDA Margin % is 20.83%, which is 48% above median its own 10-year median of 14.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genus stock overvalued right now?
Based on GuruFocus' analysis, Genus (GENSY) is currently considered Fairly Valued. The stock's GF Value™ is $29.86, compared to a current price of $31.25 — trading 4.7% above its estimated fair value. The current EBITDA Margin % is 20.83%, which is 48% above median its 10-year median of 14.11. Genus' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Genus (GENSY), the current EBITDA Margin % is 20.83% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genus (GENSY) Overvalued in 2026?
Based on GuruFocus' analysis, Genus stock appears to be overvalued.
The current stock price of $31.25 is trading 4.7% above its estimated GF Value™ of $29.86.
GuruFocus considers Genus to be Fairly Valued.
Key valuation signals for GENSY:
EBITDA Margin %: 20.83% (48% above median its 10-year median of 14.11)
GF Value™: $29.86 vs. price of $31.25 (4.7% above fair value)
No single metric tells the full story. See the GENSY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genus PLC is an animal genetics company focused on improving cattle and pig populations to support sustainable food production. The company operates through two main business units: one providing bovine genetics mainly for dairy and beef cattle, and the other offering porcine genetics for pork production. Genus develops genetically superior breeding animals using scientific techniques. It generates revenue by selling genetics, including semen and embryos, as well as through related services under multi-year royalty agreements. The principal activities of each segment are: (a) Genus PIC porcine sales business, (b) Genus ABS: bovine sales business, and (c) Genus Research and Development: spending on research and development.
55GF Score
Get the complete analysis for GENSY
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GENSY has been successfully added to your 
